Background

Asthma is a chronic, complex respiratory disorder in which allergen-triggered inflammatory reactions in the airways contribute to the development of symptoms, including breathlessness, cough, wheezing, and dyspnea. It has been estimated that asthma affect about 300 million people in the world [1]. Prognostic markers to detect high-risk individuals are urgently required for early identification and preventive attention. In the scientific community, genetic vulnerability to asthma is one of the main research interests [2]. In the recent decade, many studies have been focused to elucidate the susceptibility genes of asthma and several single nucleotide polymorphisms (SNPs) in these genes have been described to be related with asthma risk in different populations [3, 4]. Among different genes, interleukin 4 (IL-4) gene has been comprehensively investigated [5, 6]. IL-4 plays a major function in isotype class switching of B cells to IgE production, type 2 immune responses, and it is involved in recruitment of mast cell [7, 8]. It has thus been proposed that IL-4 may have an imperative role in the development and persistent of asthma [7]. IL-4 gene is located on long arm of chromosome 5 (5q31), a region that has been associated with asthma or related disorders such as bronchial hyper responsiveness (BHR) and atopy [9]. The IL-4 C33T single nucleotide polymorphism (rs2070874) which is located on the untranslated region (UTR) has been represented to be linked with elevated serum IgE levels and risk of asthma [10,11,12]. There are several studies in which association between IL-4 C33T polymorphism and asthma risk have been evaluated [5, 6, 10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31]. Nevertheless, this association remains inconsistent and inconclusive in several studies. Probably, this could be because of the small samples size examined in these studies and the small effect size of the polymorphism that failed to provide sufficient statistical power to identify statically significant associations. Accordingly, we conducted a meta-analysis to conclude a more exact estimation of the relation between the IL-4 C33T polymorphism and risk of asthma.

Methods

We carried out this meta-analysis by following the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement [32]. Since our study did not contain any experimental procedure on humans and animals, thus no ethics committee confirmation was applicable.

Search strategy

A comprehensive systematic search was applied through three major databases (MEDLINE, web of science, and Scopus) to find all potential publications considering the association between IL-4 C33T polymorphism and asthma risk released before September 2020. We searched (“asthma” [Mesh] OR “asthmatic”) AND (“interleukin-4” OR “IL-4” OR “interleukin 4”) AND (“single nucleotide polymorphism” OR “SNP” OR “polymorphisms” OR “mutation” OR “variation”), as main key words. Besides, cross reference check of review studies were screened for additional relevant papers.

Inclusion and exclusion criteria

Initial search strategy yield 1873 studies that exported to Endnote X8. The duplicate studies which were common among databases were removed and title and abstract of remain studies were reviewed by two investigators. In cases that we could not categorize retrieved studies by title and abstract, full-text verification was performed. Eventually, studies considered eligible if met the following criteria: 1) publications that evaluate the association between IL-4 C33T polymorphism and the risk of asthma; 2) publications with extractable data to estimate odds ratios (ORs) and 95% confidence intervals; 3) publications that report genotype or allele distributions of case and controls. Duplicate articles, review articles, editorials, case reports, book chapters, republished data, comments, and studies with insufficient data after contacting with authors were all excluded. The usage of these criteria results in 24 eligible paper for the meta-analysis.

Data extraction and quality assessment

Two researchers independently and according to a standard checklist extracted requisite data including: the first author family, country of origin, ethnicity, number of subjects in the case and the control groups for each gender, mean or range of age, applied genotyping method, distribution of alleles in cases and controls, journal and year of publication. The methodological quality of included study was scored using the Newcastle-Ottawa Scale (NOS) criteria [33]. Accordingly, publications with scores 0–3, 4–6 or 7–9 were low, moderate or high-quality, respectively.

Statistical analysis

All data analysis was accomplished using SPSS (version 23; Chicago, IL, USA) and Stata (version 14; Stata Corporation, College Station, TX) softwares. The strength of association between SNP and the risk of asthma was measured via Odd ratios (ORs) and 95% confidence intervals (CIs). Moreover, the degree of heterogeneity between studies was assessed by the Q test (Q-statistic P value> 0.10, no heterogeneity vs. Q-statistic P value< 0.10, significant heterogeneity) and the I2 test (I2 < 25%, no heterogeneity; I2 = 25–50%, moderate heterogeneity; I2 = 50–75%, large heterogeneity, I2 > 75%, extreme heterogeneity) [34]. In the presence of heterogeneity random effect model (REM) should be used. Otherwise, fixed effect model (FEM) should be applied [35]. To estimate whether the results were substantially changed by any individual study, sensitivity analysis by sequential omitting of each included study was performed. Furthermore, publication bias was investigated, using Begg’s and Egger’s tests along with visual examination of the funnel plot (p value< 0.05 considered statistically significant) [36].

Results

Study characteristics

A total of 1873 articles were identified through the systematic literature search of databases. After excluding 219 duplicate studies and removing 1496 irrelevant publications based on titles/abstracts, 158 studies went under full-text screening. Of which, 134 paper were excluded. Finally, twenty-four studies qualified for quantitative analysis Fig. 1. All included studies were performed between 2000 to 2016 and had good methodological score ranging 5 to 8. Case-control design was common between eligible studies and different genotyping method were used by included studies. Tables 1 and 2 summarized the characteristics and allele distribution, genotype frequency of the eligible studies.

Fig. 1
figure 1

Flow diagram of study selection process

Table 1 Characteristics of studies included in meta-analysis of overall asthma
Table 2 Distribution of genotype and allele among asthma patients and controls

Meta-analysis of IL-4 C33T polymorphism and the risk of asthma

Twenty-four studies with 6587 cases and 8408 healthy controls were included in final meta-analysis of overall population. Of them, 15 publications were carried out in Asian countries, 5 publications were in American countries and 4 publications were in Europe. The pooled OR indicated that IL-4 C33T polymorphism increase risk of asthma across all genotype models including dominant model (OR = 1.15, 95% CI = 1.04–1.26, P = ≤0.001, FEM), recessive model (OR = 1.16, 95% CI = 1.06–1.28, P = ≤0.001, FEM), allelic model (OR = 1.14, 95% CI = 1.07–1.21, P = ≤0.001, FEM), CC vs. TT model (OR = 1.21, 95% CI = 1.02–1.43, P = 0.02, FEM) and CT vs. TT model (OR = 1.10, 95% CI = 1–1.22, P = 0.05, FEM) Fig.2. The detailed findings for different analysis models are shown in Table 3.

Fig. 2
figure 2

Pooled odds ratio (OR) and 95% confidence interval of individual studies and pooled data for the association between IL-4 C33T gene polymorphism and asthma risk in overall populations for a dominant model, b recessive model

Table 3 Main results of pooled ORs in meta-analysis of IL-4 (C33T) gene polymorphisms

Subgroup analysis

We categorized studies into different subgroups on the basis of age, continent and ethnicity. The results of pooled ORs, heterogeneity tests and publication bias tests for different analysis models are reported in Table 3.

Subgroup analysis by age

In this group, we stratified included publications into three groups including: adult (8 articles), children (7 articles) and mixed (cover both ranges; 9 articles). Overall, the results rejected significant association between IL-4 C33T polymorphism and risk of asthma in different age group except for allelic model [adults (OR = 1.14, 95% CI = 1.02–1.26, P = 0.02, FEM), mixed (OR = 1.14, 95% CI = 1.01–1.29, P = 0.03, REM), children (OR = 1.13, 95% CI = 1.04–1.24, P = ≤0.001, FEM)] and recessive model (just in children (OR = 1.18, 95% CI = 1.03–1.35, P = 0.01, REM)) Fig. 3.

Fig. 3
figure 3

Pooled odds ratio (OR) and 95% confidence interval of individual studies and pooled data for the association between IL-4 C33T gene polymorphism and asthma risk in different subgroup analysis: a allelic model, b recessive model, c dominant model

Subgroup analysis by continent

Our included studies performed in Asia (15 articles), Europe (4 articles), America (4 articles), and Oceania (1 article). Since there was only one study for Oceania, we exclude it. The final findings indicated strong significant association between IL-4 C33T polymorphism and asthma risk in European population across dominant model (OR = 1.23, 95% CI = 1.01–1.50, P = 0.03, FEM), recessive model (OR = 2.94, 95% CI = 1.54–5.62, P = ≤0.001, FEM), allelic model (OR = 1.30, 95% CI = 1.10–1.54, P = ≤0.001, FEM) and CC vs. TT (OR = 3, 95% CI = 1.56–5.76, P = ≤0.001, FEM). Moreover, there was a significant association between IL-4 C33T polymorphism and risk of asthma in American population under dominant model (OR = 1.26, 95% CI = 1.05–1.51, P = ≤0.001, FEM), allelic model (OR = 1.17, 95% CI = 1.03–1.33, P = 0.01, FEM), and CT vs. TT model (OR = 1.23, 95% CI = 1.02–1.49, P = 0.03, FEM). Eventually, Significant positive association was revealed in Asians just in recessive model (OR = 1.14, 95% CI = 1.02–1.26, P = 0.01, FEM), and allelic model (OR = 1.12, 95% CI = 1.03–1.21, P = ≤0.001, FEM) Fig. 3.

Subgroup analysis by ethnicity

Finally, we stratified eligible articles according ethnicity including Caucasians (20 articles), and African-Americans (4 articles). The results showed significant association between IL-4 SNP (C33T) and asthma risk in Caucasians under dominant model (OR = 1.15, 95% CI = 1.04–1.28, P = 0.008, FEM), recessive model (OR = 1.17, 95% CI = 1.06–1.30, P = 0.002, FEM), allelic model (OR = 1.14, 95% CI = 1.07–1.22, P = ≤0.001, FEM),and CC vs. TT model (OR = 1.23, 95% CI = 1.01–1.49, P = 0.03, FEM) but not CT vs. TT model (OR = 1.1, 95% CI = 0.98–1.22, P = 0.09, FEM). However, there was no significant association between IL-4 C33T polymorphism and risk of asthma in American-African population across all genotype models Fig. 3.

Evaluation of heterogeneity

No significant heterogeneity was detected for IL-4 C33T polymorphism neither in overall population nor subgroup analysis, therefore we did not perform mete-regression analysis for possible parameters (Table 3).

Sensitivity analysis and publication bias

Begg’s and Egger’s tests were performed to estimate the publication biases of studies. As showed in Table 3 no evidence of publication bias was detected in overall populations and subgroup analysis. Also, symmetric shape of Begg’s funnel plot confirm this finding Fig. 4. Moreover, the impact of individual study on pooled OR was evaluated by sensitivity analysis, which confirmed stability of our results Fig. 5.

Fig. 4
figure 4

Begg’s funnel plot for publication bias test. Dominant model IL-4 C33T. Each point represents a separate study for the indicated association

Fig. 5
figure 5

Sensitivity analysis in present meta-analysis investigates the single nucleotide polymorphisms of IL-4 C33T contribute to risk for asthma

Discussion

The cytokine IL-4 act as a key player in the development and pathogenesis of allergic inflammation [37] and atopy [38] through the induction of the heavy chain isotype switching, secretion of IgE antibody (IgE synthesis) by B cells, functioning as a growth factor for Th2 cells [37]. The IL-4 promotes IgE-dependent immune responses as it induces overexpression of IgE receptors on the surface of various immune cells: FcεRI on basophils and mast cells; and FcεRII (CD23) on mononuclear phagocytic cells and B lymphocytes [39]. The IL-4 tilts the immune response to anti-inflammatory, inhibiting macrophages pro-inflammatory effect and downregulating secretion of pro-inflammatory cytokines [40]. The IL-4 critically, initiate immediate allergic responses by triggering IgE-mediated mast cell activation [41]. The IL-4 plays a pivotal role in the priming of naïve T cell towards Th2 differentiation as well as exacerbate allergic inflammation through induction of vascular adhesion molecule 1 (VCAM-1) that recruit leukocytes and promote their survival [39]. The IL-4 induce airway remodeling encountered in asthma by its role in the proliferation of bronchial fibroblasts, myofibroblasts, and airway smooth muscles [38].

At the turn of the millennium genetic polymorphisms of the IL-4 gene in the development and maintenance of asthma have drawn increasing consideration. Modulation of the immune system is the common denominator in IL-4 polymorphisms [40]. Suzuki and coworkers found a single nucleotide polymorphism of C replacement of T at position 33 bp of exon 1 (C33T) of the IL-4 proximal promoter region [42]. Asthmatic patients with C33T have higher serum level of IL-4 and IgE [43]. Anovazzi and colleagues studied IL-4 haplotypes and reported that the studied haplotypes induce an opposing immune response, as well they recorded minimal functional activity in polymorphisms involving the promoter region [40]. An increasing body of evidence has demonstrated that C33T of the IL-4 gene untranslated region (UTR) of chromosome 5q was associated with elevated serum IgE levels and the risk of asthma [44, 45]. However, this association remains inconclusive. If this is indeed the case, a meta-analysis with big sample size, sufficient statistical power, and subgroup analysis was needed.

Our current meta-analysis composed of 24 publications (28 studies) involving 6587 cases and 8408 controls, we systematically assessed the relationship between IL-4 C33T polymorphism and asthma susceptibility. Cumulatively, the result illustrated IL-4 C33T polymorphism as a risk factor in the pathogenesis of asthma. The result indicated that the presence of T allele across different genetic models increased asthma risk by 10 to 21%. In the subgroup analysis by age, the results rejected the significant association between IL-4 C33T polymorphism and risk of asthma in different age groups except for allelic model, which highlighted the predisposing role of the T allele for the asthma risk in all three age groups. Subgroup analysis by continent revealed a significant association between IL-4 C33T polymorphism and asthma risk in the European population. In the Asian population, there was a significant association between IL-4 C33T polymorphism and the risk of asthma under recessive and allelic models. In contrast, the American population showed a significant association under dominant and allelic models.

Additionally, subgroup analysis was conducted according to ethnicity; the results showed a significant association between IL-4 C33T polymorphism and asthma risk in Caucasians under all models except CT vs TT model. While, no significant association between IL-4 C33T polymorphism and the risk of asthma in the American-African population were detected.

It should be noted that our results are not in agreement with those of Liu et al. [46] meta-analysis on the role of IL-4 C33T polymorphism and asthma. They suggested a significant association between whites and Asians. While they reported a significant association between the IL-4 C33T polymorphism and asthma risk in the overall population, they did not find a significant association among atopic and non-atopic asthma patients in subgroup analysis. Furthermore, in contrast to our meta-analysis, in the subgroup analysis by age, they reported an increased risk of asthma among children but not in the adult. Finally, while they reported evidence of publication bias, we identified no evidence of publication bias for the overall population and subgroup analysis under all genetic models.

The main reason for these discrepancies raised could be from the fact that Liu and colleagues included 18 studies with 5523 cases and 5618 controls. However, our meta-analysis encompasses 28 studies including 6587 cases and 8408 controls from different ethnicities and continents.

The C33T single nucleotide polymorphism is detected on the 5′ untranslated regions (UTR) of the IL-4 gene [42]. The 5′ UTRs region of mRNA may contain many gene regulatory elements (GRE) that regulate the localization, translation and degradation of transcripts [47]. In the eukaryotic mRNAs, the 5′ UTRs regulate both cap-dependent and cap-independent translation initiation of mRNA [48]. Researchers revealed a relationship between IL-4 C33T polymorphism and elevated serum IgE levels in a group of the Japanese population [49]. While the exact mechanisms by which the IL-4 C33T allele modulates the gene expression of the IL-4 remain elusive, it has been suggested that this variation may influence the stability of mRNA, as well as transcriptional or translational efficiency of the IL-4 gene, highlighting that the 5′ UTR may involve many cis-acting elements [47, 50,51,52].

Heterogeneity and publication bias, which may affect the results of meta-analyses, should always be considered. The result of this study did not show significant heterogeneity. Moreover, there was no significant publication bias in the overall population and subgroup analysis under all genetic models. Consequently, heterogeneity and publication bias did not appear to have inclined the results. Sensitivity analyses were also performed. There was a little variation of the estimates after exclusion of a single study and the significance of the pooled ORs was not affected proposing the consistency of this result.

The current study had some limitations. First, most included articles were from the Asia continent with Caucasian race and there was no study from Africans; accordingly, the results of this meta-analysis may not be appropriate to Africans. Second, in some studies, the diagnostic criteria and asthma phenotype were not clearly determined; while the asthma diagnostic criteria were primarily based on physical examination, clinical history, and pulmonary function tests (PFT), there did exist a little dissimilarity among studies. Third, the overall results were based on unadjusted estimates; a more precise evaluation should be accompanied when all singular raw data are accessible, which would facilitate the adjustment by other potential co-variants such as; age, gender, obesity, environmental factors, smoking status, and other lifestyles. Fourth, due to a lack of extractable data, we failed to address gene-environment and gene-gene interactions. In contrast to these limitations, two main strengths of our meta-analysis include; Firstly, a large number of patients and the healthy individuals were pooled from various studies, which considerably augment the statistical power of the meta-analysis. Secondly, no evidence of publication biases was identified, representing that the whole collected data may be unbiased.

Conclusion

Taken together, this study suggests that IL-4 C33T polymorphism potentially acts as a risk factor for asthma in different ethnicities and age groups. Nevertheless, large sample studies from different continents and races with homogeneous asthmatic patients and well-matched healthy subjects are still needed. Furthermore, gene-environment and gene-gene interactions should also be regarded in future studies. With taking these factors into account in future studies, it would ultimately lead to our comprehensive and better understanding of the association between the IL-4 C33T polymorphism and asthma susceptibility.